A Study of OSI-7904L as Treatment in Patients With Head and Neck Cancer Who Have Failed First-Line Therapy

Completed · Phase 2

Conditions studied: Locally Recurrent or Metastatic Cancer of the Head and Neck, Must Have Failed First-Line Therapy

In brief

Multi-center, Phase II study to evaluate the efficacy and safety of OSI-7904Lin head and neck cancer in patients who have failed first-line therapy

Key facts

Study ID

NCT00116909

Run by

OSI Pharmaceuticals

People needed

85

Starts

2004-08-01

Expected to finish

2005-08-01

Last updated by the study team

2007-03-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically or cytologically confirmed metastatic or locally recurrent SCCHN that is incurable with surgery or radiation therapy ECOG performance status 0-2 No more tha 1 prior chemotharapy regimen for metastatic or locally recurrent disease Adequate bone marrow, Hepatic and renal function. At least one target lesion greater than or equal to 20 mm.

You may not qualify if…

• Symptomatic brain metasteses which are not stable, are not adequately controlled, are potenially life threatening or required radiation in the last 28 days Pregnant or lactating women. Concurrent anticancer therapy or other investigational drugs Patients with active or uncontrolled infections or other serious illnesses or medical conditions.

Where it is running

• Dana-Farber Cancer Institute — Boston, Massachusetts, United States
• Stony Brook University Hospital — Stony Brook, New York, United States
• Sarah Cannon Cancer Center — Nashville, Tennessee, United States
• The Vanderbilt Cancer Center — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.